Observational studyClinical and experimental medicine2025
Clinical characteristics and treatment patterns of systemic sclerosis patients in China: a single-center retrospective study.
Observational study in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to describe the demographic, laboratory, and clinical characteristics of systemic sclerosis (SSc) patients in a Chinese national tertiary referral center, and to outline the treatment model. A retrospective observational study was conducted on adult SSc patients admitted to Peking Union Medical College Hospital between January 2012 and January 2022. Data were collected from electronic medical records, including demographics, clinical, laboratory parameters, and treatment details, and analyzed using SPSS. This study included 232 SSc patients, with 45.7% classified as diffuse cutaneous SSc (dcSSc) and 54.3% as limited cutaneous SSc (lcSSc). Anticentromere antibody and anti-topoisomerase I antibody were more common in lcSSc (33.3%) and dcSSc (36.2%), respectively. Excluding skin manifestations, the most common organ involvement was gastrointestinal, particularly esophageal involvement (56.5%), followed by diastolic dysfunction (53.2%), pericardial effusion (48.9%), pulmonary arterial hypertension (PAH) (44.8%), and lung fibrosis (20.1%). Combined immunosuppressive therapy was common, with 85.1% and 51.8% of patients receiving glucocorticoids and cyclophosphamide, respectively; medications for complication management, such as proton pump inhibitors (64.5%) for gastrointestinal involvement, were also frequently prescribed. Additionally, traditional Chinese medicine was incorporated into the regimen for almost one-quarter (23.7%) of patients. Multivariate analysis revealed that elevated N-terminal pro-brain natriuretic peptide and elevated C-reactive protein were significantly associated with PAH (OR = 12.359 and 3.239). This study delineates a clinical profile of Chinese SSc patients characterized by frequent multi-organ involvement and a common practice of combined immunosuppressive therapy. Further exploration is needed to develop more precise pharmacological strategies and to identify predictive factors for SSc-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.